Agents Under Investigation in AML

Now that the FDA has lifted the partial clinical hold on the phase 1 study of FHD-286 in patients with relapsed/refractory acute myelogenous leukemia and myelodysplastic syndrome, there are plans to initiate a trial to further assess the agent with decitabine or cytarabine.

In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.

In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed drug shortages and how they are affecting clinicians and patients in the oncology space.

In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.

Phase 2 FELIX study results show 21.3% of the 94 patients infused with obecatagene autoleucel achieved a complete response or complete response with incomplete count recovery.

In a phase 3 study, imetelstat has shown prolonged transfusion independence and hemoglobin increase in the relapsed or refractory myelodysplastic syndrome population.